ArrowMark Colorado Holdings LLC Takes Position in CeriBell (NASDAQ:CBLL)

ArrowMark Colorado Holdings LLC acquired a new stake in CeriBell (NASDAQ:CBLL - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 75,000 shares of the company's stock, valued at approximately $1,941,000. ArrowMark Colorado Holdings LLC owned approximately 0.21% of CeriBell at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Legal & General Group Plc acquired a new stake in shares of CeriBell in the fourth quarter valued at $32,000. Summit Investment Advisors Inc. purchased a new position in shares of CeriBell in the 4th quarter valued at about $33,000. Tower Research Capital LLC TRC acquired a new position in shares of CeriBell during the fourth quarter worth about $37,000. PNC Financial Services Group Inc. purchased a new stake in shares of CeriBell during the fourth quarter worth approximately $47,000. Finally, Corebridge Financial Inc. acquired a new stake in CeriBell in the fourth quarter valued at approximately $158,000.

Insider Buying and Selling at CeriBell

In other news, CEO Xingjuan Chao sold 5,700 shares of the stock in a transaction on Thursday, April 17th. The stock was sold at an average price of $15.02, for a total transaction of $85,614.00. Following the sale, the chief executive officer now owns 746,451 shares in the company, valued at approximately $11,211,694.02. This represents a 0.76 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders sold 24,700 shares of company stock worth $372,434 over the last ninety days.

Analysts Set New Price Targets

A number of analysts have weighed in on the company. Canaccord Genuity Group restated a "buy" rating and issued a $33.00 price target on shares of CeriBell in a research note on Wednesday, February 26th. LADENBURG THALM/SH SH started coverage on CeriBell in a report on Friday, April 4th. They issued a "buy" rating and a $32.00 price target for the company. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat, CeriBell currently has a consensus rating of "Buy" and an average price target of $32.50.

CeriBell Price Performance

NASDAQ CBLL traded up $0.24 during trading hours on Wednesday, reaching $16.01. 342,018 shares of the company traded hands, compared to its average volume of 271,382. The stock has a 50 day simple moving average of $18.36. CeriBell has a 12 month low of $10.01 and a 12 month high of $32.75.

CeriBell (NASDAQ:CBLL - Get Free Report) last released its earnings results on Tuesday, February 25th. The company reported ($0.40) earnings per share for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.08). The business had revenue of $18.53 million during the quarter, compared to analysts' expectations of $17.55 million. As a group, analysts anticipate that CeriBell will post -2.46 EPS for the current year.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.